Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIERRA: durvalumab + tremelimumab first-line treatment for advanced hepatocellular carcinoma
2022-502012-37-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of durvalumab and tiragolumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Incidence of Grade 3/4 PRAEs within 6 months and Objective response rate. Planned start Aug 2023; status: authorised.
02
Drugs
durvalumabtiragolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-502012-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502012-37-00.